{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:33:00Z","timestamp":1792528380549,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA228166"],"award-info":[{"award-number":["CA228166"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy. Besides severe respiratory and systematic symptoms, several comorbidities increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we report that SARS-CoV-2 encoded proteins and some currently used anti-COVID-19 drugs are able to induce lytic reactivation of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses, through manipulation of intracellular signaling pathways. Our data indicate that those KSHV\u2009+\u2009patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.<\/jats:p>","DOI":"10.1038\/s42003-021-02220-z","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T06:14:48Z","timestamp":1622700888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus"],"prefix":"10.1038","volume":"4","author":[{"given":"Jungang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlie","family":"Plaisance-Bonstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-1275","authenticated-orcid":false,"given":"Zhiqiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"2220_CR1","doi-asserted-by":"crossref","unstructured":"Calina, D. et al. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol. Res. 68, 315\u2013324 (2020).","DOI":"10.1007\/s12026-020-09154-4"},{"key":"2220_CR2","doi-asserted-by":"crossref","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2020).","DOI":"10.1038\/s41579-020-00459-7"},{"key":"2220_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2220_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"2220_CR5","doi-asserted-by":"publisher","unstructured":"Elezkurtaj, S. et al. Causes of death and comorbidities in patients with COVID-19. medRxiv https:\/\/doi.org\/10.1101\/2020.06.15.20131540 (2020).","DOI":"10.1101\/2020.06.15.20131540"},{"key":"2220_CR6","doi-asserted-by":"crossref","unstructured":"Bennett, S. et al. Clinical features and outcomes of adults with COVID-19: a systematic review and pooled analysis of the literature. Int. J. Clin. Pract. 75, e13725 (2020).","DOI":"10.1111\/ijcp.13725"},{"key":"2220_CR7","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 266, 1865\u20131869 (1994).","journal-title":"Science"},{"key":"2220_CR8","doi-asserted-by":"crossref","unstructured":"Broussard, G. & Damania, B. Regulation of KSHV latency and lytic reactivation. Viruses 12 1034 (2020).","DOI":"10.3390\/v12091034"},{"key":"2220_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ996","volume":"62","author":"MN Polizzotto","year":"2016","unstructured":"Polizzotto, M. N. et al. Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin. Infect. Dis. 62, 730\u2013738 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"2220_CR10","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.3389\/fimmu.2019.03084","volume":"10","author":"G Broussard","year":"2019","unstructured":"Broussard, G. & Damania, B. KSHV: immune modulation and immunotherapy. Front. Immunol. 10, 3084 (2019).","journal-title":"Front. Immunol."},{"key":"2220_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fmicb.2017.00613","volume":"8","author":"KK Aneja","year":"2017","unstructured":"Aneja, K. K. & Yuan, Y. Reactivation and lytic replication of Kaposi\u2019s SArcoma-associated Herpesvirus: an Update. Front. Microbiol. 8, 613 (2017).","journal-title":"Front. Microbiol."},{"key":"2220_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jviromet.2011.03.012","volume":"174","author":"J Myoung","year":"2011","unstructured":"Myoung, J. & Ganem, D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174, 12\u201321 (2011).","journal-title":"J. Virol. Methods"},{"key":"2220_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e278 (2020).","journal-title":"Cell"},{"key":"2220_CR14","doi-asserted-by":"crossref","unstructured":"Fiolet, T. et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin. Microbiol. Infect. 27, 19\u201327 (2021).","DOI":"10.1016\/j.cmi.2020.08.022"},{"key":"2220_CR15","doi-asserted-by":"crossref","unstructured":"Osawa, I. et al. Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. J. Thromb. Thrombolysis 51, 649\u2013656 (2021).","DOI":"10.1007\/s11239-020-02275-5"},{"key":"2220_CR16","doi-asserted-by":"crossref","unstructured":"Maciorowski, D. et al. A review of the preclinical and clinical efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir treatments against COVID-19. SLAS Discov. 25, 1108\u20131122 (2020).","DOI":"10.1177\/2472555220958385"},{"key":"2220_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3389\/fphar.2020.01333","volume":"11","author":"TS Schoot","year":"2020","unstructured":"Schoot, T. S., Kerckhoffs, A. P. M., Hilbrands, L. B. & van Marum, R. J. Immunosuppressive drugs and COVID-19: a review. Front Pharm. 11, 1333 (2020).","journal-title":"Front Pharm."},{"key":"2220_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri, E. A., Cesarman, E. & Boshoff, C. Kaposi\u2019s sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10, 707\u2013719 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2220_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1469-0691.12340","volume":"20","author":"Y Cao","year":"2014","unstructured":"Cao, Y. et al. High prevalence of early childhood infection by Kaposi\u2019s sarcoma-associated herpesvirus in a minority population in China. Clin. Microbiol. Infect. 20, 475\u2013481 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"2220_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ijc.31863","volume":"144","author":"NK El-Mallawany","year":"2019","unstructured":"El-Mallawany, N. K. et al. KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma\u2014exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. Int. J. Cancer 144, 110\u2013116 (2019).","journal-title":"Int. J. Cancer"},{"key":"2220_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/infdis\/jiy262","volume":"218","author":"R Newton","year":"2018","unstructured":"Newton, R. et al. Determinants of gammaherpesvirus shedding in saliva among Ugandan children and their mothers. J. Infect. Dis. 218, 892\u2013900 (2018).","journal-title":"J. Infect. Dis."},{"key":"2220_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/PHMT.S142816","volume":"9","author":"NK El-Mallawany","year":"2018","unstructured":"El-Mallawany, N. K., McAtee, C. L., Campbell, L. R. & Kazembe, P. N. Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. Pediatr. Health Med. Ther. 9, 35\u201346 (2018).","journal-title":"Pediatr. Health Med. Ther."},{"key":"2220_CR23","doi-asserted-by":"crossref","unstructured":"Bogiatzopoulou, A. et al. COVID-19 in children: what did we learn from the first wave? Paediatr. Child Health 30, 438\u2013443 (2020).","DOI":"10.1016\/j.paed.2020.09.005"},{"key":"2220_CR24","doi-asserted-by":"crossref","unstructured":"Drago, F., Ciccarese, G., Rebora, A. & Parodi, A. Human herpesvirus 6, 7 and Epstein Barr virus reactivation in pityriasis rosea during COVID-19. J. Med. Virol. 93, 1850\u20131851 (2021).","DOI":"10.1002\/jmv.26549"},{"key":"2220_CR25","doi-asserted-by":"crossref","unstructured":"Xu, R. et al. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br. J. Dermatol. 183, 1145\u20131147 (2020).","DOI":"10.1111\/bjd.19484"},{"key":"2220_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/ijd.15001","volume":"59","author":"F Tartari","year":"2020","unstructured":"Tartari, F. et al. Herpes zoster in COVID-19-positive patients. Int. J. Dermatol 59, 1028\u20131029 (2020).","journal-title":"Int. J. Dermatol"},{"key":"2220_CR27","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-09-4663","volume":"70","author":"Z Qin","year":"2010","unstructured":"Qin, Z., Dai, L., Slomiany, M. G., Toole, B. P. & Parsons, C. Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res. 70, 3884\u20133889 (2010).","journal-title":"Cancer Res."},{"key":"2220_CR28","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.18632\/oncotarget.6584","volume":"7","author":"L Dai","year":"2016","unstructured":"Dai, L. et al. CD147 and downstream ADAMTSs promote the tumorigenicity of Kaposi\u2019s sarcoma-associated herpesvirus infected endothelial cells. Oncotarget 7, 3806\u20133818 (2016).","journal-title":"Oncotarget"},{"key":"2220_CR29","unstructured":"Wang, K. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 5, 283 (2020)."},{"key":"2220_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.virol.2004.03.049","volume":"325","author":"J Vieira","year":"2004","unstructured":"Vieira, J. & O\u2019Hearn, P. M. Use of the red fluorescent protein as a marker of Kaposi\u2019s sarcoma-associated herpesvirus lytic gene expression. Virology 325, 225\u2013240 (2004).","journal-title":"Virology"},{"key":"2220_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.virol.2019.07.024","volume":"536","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. Expression of PD-1 and PD-Ls in Kaposi\u2019s sarcoma and regulation by oncogenic herpesvirus lytic reactivation. Virology 536, 16\u201319 (2019).","journal-title":"Virology"},{"key":"2220_CR32","first-page":"687","volume":"1","author":"MR Defee","year":"2011","unstructured":"Defee, M. R. et al. Extracellular Hsp90 serves as a co-factor for NF-kappaB activation and cellular pathogenesis induced by an oncogenic herpesvirus. Am. J. Cancer Res. 1, 687\u2013700 (2011).","journal-title":"Am. J. Cancer Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02220-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T14:26:37Z","timestamp":1670077597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02220-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-02220-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.02.324228","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"682"}}